NTRK1 and hepatocellular carcinoma: Sorafenib and lenvatinib are small‐molecule inhibitors of multiple receptor tyrosine kinases and are first‐line therapeutic drugs for advanced HCC patients.[5, 22] Nevertheless, only a small proportion of HCC patients exhibit satisfactory therapeutic effects.